The Clinical Efficacy of Adding Ceftazidime/Avibactam to Standard Therapy in Treating Infections Caused by Carbapenem-Resistant <i>Klebsiella pneumonia</i> with blaOXA-48-like Genes

• Autori principali: Al Maamon R. Abu Jaber (Autore), Bilgen Basgut (Autore), Ali Abdullah Hawan (Autore), Ali Amer Al Shehri (Autore), Sultan Ahmad AlKahtani (Autore), Nehad J. Ahmed (Autore), Abdikarim Abdi (Autore)
• Natura: Libro
• Pubblicazione: MDPI AG, 2024-03-01T00:00:00Z.
• Soggetti: article
• Accesso online: Connect to this object online.

Ceftazidime/avibactam (CAZ-AVI) is FDA-approved for managing infections caused by resistant gram-negative bacilli, particularly infections via carbapenem-resistant <i>Enterobacterales</i> pathogens. The clinical data are still limited, particularly those in Saudi Arabia. The present stud...